Publications by authors named "F Jehl"

Claim this Profile
S
Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint.
Julien Massol, Aurélien Dinh, Katy Jeannot, Clara Duran, Frédérique Bouchand, François Jehl

J Glob Antimicrob Resist· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel.
Eric Senneville, Guillermo Cuervo, Matthieu Gregoire, Carmen Hidalgo-Tenorio, François Jehl

Int J Antimicrob Agents· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues.
Romain Garreau, Damien Montange, Antoine Grillon, François Jehl, Tristan Ferry

Clin Pharmacokinet· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in France.
Thierry Naas, Gerard Lina, Anne Santerre Henriksen, Christopher Longshaw, Francois Jehl

JAC Antimicrob Resist· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Watch Out for a Second SNP: Focus on Multi-Nucleotide Variants in Coding Regions and Rescued Stop-Gained.
Fabien Degalez, Frédéric Jehl, Kévin Muret, Maria Bernard, Frédéric Lecerf

Front Genet· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis